Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q1

8129.TEDINET S100OXRX
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥323.4bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥1.27T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥308.8bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥1.4bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥635m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥3.1bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥18.2bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.3bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥3.0bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥2.4bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.7bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥1.7bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥710.1bnat 2022-06-30Cons.Assets
Total assets¥702.4bnat 2022-03-31Cons.Assets
Total assets¥697.5bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥466.3bnat 2022-06-30Cons.Liabilities
Total liabilities¥461.1bnat 2022-03-31Cons.Liabilities
Net assets / equity¥243.7bnat 2022-06-30Cons.Net assets
Net assets / equity¥241.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥237.4bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥94.4bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥94.3bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥29.222022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥189.72021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥24.552021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥26.862022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥174.482021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥22.552021-04-01 → 2021-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio34.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.0%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥14.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥14.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥401m
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-06-30¥22.2bn
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-06-30¥22.2bn
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-06-30¥133m
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-06-30¥612m
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.9bn
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-06-30¥288m
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-06-30¥311.8bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-06-30¥299.4bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥12.4bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.3bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥1.5bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.2bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥356m
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥94m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥338.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥323.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥14.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥1.8bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥14.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥14.5bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥466m
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue2021-04-01 → 2021-06-30¥22.5bn
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2021-04-01 → 2021-06-30¥22.5bn
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥0
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2021-04-01 → 2021-06-30¥350m
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2021-04-01 → 2021-06-30¥403m
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1.5bn
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2021-04-01 → 2021-06-30¥195m
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue2021-04-01 → 2021-06-30¥297.6bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue external2021-04-01 → 2021-06-30¥284.9bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥12.7bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentsegment profit2021-04-01 → 2021-06-30¥554m
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.3bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥966m
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥305m
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥0
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥323.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥308.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥14.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥1.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 420
ItemContextValueUnit
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-845000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration1467000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration47000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration11000000JPY
Other comprehensive incomePrior1YTDDuration-797000000JPY
Other comprehensive incomeCurrentYTDDuration1478000000JPY
Comprehensive incomePrior1YTDDuration941000000JPY
Comprehensive incomeCurrentYTDDuration3548000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration933000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration3540000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration7000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration8000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsRetailReportableSegmentsMember284929000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02608-000DispensingPharmacyReportableSegmentsMember22528000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember403000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02608-000OtherRelatedBusinessReportableSegmentMember966000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember308828000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration308828000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsRetailReportableSegmentsMember12694000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02608-000DispensingPharmacyReportableSegmentsMember0JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember1544000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02608-000OtherRelatedBusinessReportableSegmentMember305000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember14545000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-14545000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsRetailReportableSegmentsMember297624000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02608-000DispensingPharmacyReportableSegmentsMember22529000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember1948000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02608-000OtherRelatedBusinessReportableSegmentMember1272000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember323374000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-14545000000JPY
Net salesPrior1YTDDuration308828000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsRetailReportableSegmentsMember554000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02608-000DispensingPharmacyReportableSegmentsMember350000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember195000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02608-000OtherRelatedBusinessReportableSegmentMember-0JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember1101000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-466000000JPY
Operating incomePrior1YTDDuration635000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsRetailReportableSegmentsMember299409000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02608-000DispensingPharmacyReportableSegmentsMember22223000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember612000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02608-000OtherRelatedBusinessReportableSegmentMember1152000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember323397000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration323397000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsRetailReportableSegmentsMember12383000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02608-000DispensingPharmacyReportableSegmentsMember0JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember1872000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass